Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml

The Journal of Urology
David K OrnsteinEmanuel F Petricoin

Abstract

Artificial intelligence based pattern recognition algorithms have been developed and successfully used to analyze complex serum proteomic data streams generated by surface enhanced, laser desorption ionization time-of-flight mass spectroscopy. In the current study we used a high performance, hybrid quadrupole time-of-flight mass spectrometer to generate discriminatory serum proteomic profiles to determine if this technology could be used to determine the need for prostate biopsy in men with elevated prostate specific antigen (PSA). Serum samples were collected from 154 men with serum PSA 2.5 to 15.0 ng/ml and/or abnormal digital rectal examination prior to transrectal ultrasound guided biopsy. Serum samples were applied to WCX2 (weak cation exchange protein chip) Protein Arrays (Ciphergen Biosystems, Fremont, California) by a Biomek 2000 robotic liquid handler (Beckman-Coulter, Chaska, Minnesota) and low molecular weight (less than 20 kDa) proteomic patterns were generated with an API QSTAR Pulsar i LC/MS/MS System (Applied Biosystems, Framingham, Massachusetts). High resolution mass spectra were analyzed with a pattern recognition bioinformatics tool, that is Proteome Quest beta version 1.0 (Correlogic Systems, Inc., Bethesda,...Continue Reading

References

Mar 16, 2001·Expert Opinion on Pharmacotherapy·D K Ornstein, R S Pruthi
Feb 28, 2002·Lancet·Emanuel F PetricoinLance A Liotta
Sep 5, 2002·Nature Reviews. Drug Discovery·Emanuel F PetricoinLance A Liotta
Oct 17, 2002·Journal of the National Cancer Institute·Emanuel F PetricoinLance A Liotta
Mar 26, 2003·Clinical Chemistry·Emanuel F Petricoin, Lance A Liotta
Apr 3, 2003·Nature Reviews. Cancer·Julia D WulfkuhleEmanuel F Petricoin
Apr 11, 2003·Proteomics·Mamoun AhramMichael R Emmert-Buck
Jul 25, 2003·Expert Review of Molecular Diagnostics·Thomas P ConradsTimothy D Veenstra
Oct 31, 2003·Nature·Lance A LiottaEmanuel Petricoin
Apr 1, 2003·Analytical Chemistry·Haleem J IssaqTimothy D Veenstra

❮ Previous
Next ❯

Citations

May 2, 2006·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Jesús García-FoncillasNatalia Remírez
Sep 13, 2013·Der Urologe. Ausg. A·J NeuhausJ-U Stolzenburg
Oct 17, 2007·Langenbeck's Archives of Surgery·Jens K HabermannUwe J Roblick
Oct 17, 2006·Current Oncology Reports·James E Allison, Michael Lawson
Jul 9, 2013·Biochimica Et Biophysica Acta·Brian FlatleyRainer Cramer
Jan 28, 2004·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Michael E FranksAlex Sparreboom
May 21, 2011·Journal of Proteomics·Sandipan RaySanjeeva Srivastava
Sep 2, 2006·Journal of Proteome Research·Mones Abu-AsabHakima Amri
Dec 4, 2008·Asian Journal of Andrology·Sachin Agrawal, William D Dunsmuir
Jul 23, 2004·Nature·Michael MorleyVivian G Cheung
Nov 10, 2006·Nature Reviews. Cancer·Emanuel F PetricoinLance A Liotta
Sep 24, 2005·The New England Journal of Medicine·Olivera J Finn
Feb 17, 2005·Journal of the National Cancer Institute·Lance A LiottaEmanuel F Petricoin
Dec 13, 2005·Critical Care Medicine·Gerard T Hoehn, Anthony F Suffredini
Nov 26, 2010·Current Opinion in Oncology·Amelie Plymoth, Pierre Hainaut
Jan 15, 2008·Pancreas·Jay S HanasDaniel J Brackett
Oct 13, 2007·Journal of Bioinformatics and Computational Biology·Wayne G FisherHarold R Garner
Jul 21, 2010·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Raghu SinhaKaram El-Bayoumy
Jan 6, 2006·The Journal of Clinical Investigation·Josep VillanuevaPaul Tempst
Dec 19, 2008·BMC Bioinformatics·Brian T Luke, Jack R Collins
Mar 5, 2010·BMC Medical Informatics and Decision Making·Caroline S DorfmanKathryn L Taylor
Jul 19, 2006·Diagnostic Pathology·Shaheen Emmanuel Lakhan
May 19, 2009·Clinical Chemistry and Laboratory Medicine : CCLM·Peter Findeisen, Michael Neumaier
Jun 20, 2014·Proteome Science·Stefania BergaminiAldo Tomasi
Mar 16, 2007·Expert Review of Medical Devices·Nicholas J FitzsimonsJudd W Moul
Jul 5, 2008·Expert Review of Molecular Diagnostics·Jimmy Lin, Meng Li
Jul 8, 2005·Expert Review of Proteomics·Dobrin Nedelkov
Dec 1, 2008·Expert Opinion on Medical Diagnostics·Urban A Kiernan
Jan 8, 2005·Clinical Prostate Cancer·Oliver Sartor
Apr 19, 2008·Clinica Chimica Acta; International Journal of Clinical Chemistry·Michael PhillipsJames Wai
Mar 4, 2008·Seminars in Radiation Oncology·Bradly G Wouters
Apr 1, 2008·Surgical Oncology Clinics of North America·Alexander A ParikhNipun B Merchant
Dec 2, 2006·Urologic Oncology·Timothy J BradfordArul M Chinnaiyan
Jan 1, 2009·Proteomics. Clinical Applications·Magnus PalmbladRainer Cramer
May 9, 2006·Urologic Oncology·David K Ornstein, Darren R Tyson
Sep 7, 2005·Gastroenterology·Carol R Regueiro, UNKNOWN AGA Future Trends Committee
Jul 30, 2011·Bioorganic & Medicinal Chemistry Letters·Sarah C HubbardCarolyn R Bertozzi
Dec 30, 2006·Biochemical and Biophysical Research Communications·Amosy E M'KomaNeil A Bhowmick
Nov 28, 2007·Annual Review of Pathology·Scott A TomlinsArul M Chinnaiyan
Jun 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Norman J Maitland, Anne T Collins
Sep 2, 2009·Anais Da Academia Brasileira De Ciências·Luis E C Andrade
Dec 16, 2005·The Surgeon : Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland·N A Henderson, R J C Steele

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.